Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Bioequivalence Study of HUC2-344 vs Co-administered Components in Healthy Volunteers
NCT06552182Phase 1Completed
- Sponsor
- Huons
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Huons. Primary endpoints: Maximum Plasma Concentration (Cmax) at 48 hours, Time to Maximum Plasma Concentration (Tmax) at 48 hours and 1 more. Started Jan 2024; status: completed.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06552182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552182.